Towardsin silicodesignof epitope-basedvaccines

Background: Epitope-based vaccines (EVs) make use of immunogenic peptides (epitopes) to trigger an immune response. Due to their manifold advantages, EVs have recently been attracting growing interest. The success of an EV is determined by the choice of epitopes used as a basis. However, the experimental discovery of candidate epitopes is expensive in terms of time and money. Furthermore, for the final choice of epitopes various immunological require- ments have to be considered. Methods: Numerous in silico approaches exist that can guide the design of EVs. In particular, computational methods for MHC binding prediction have already become standard tools in immunology. Apart from binding prediction and prediction of antigen processing, methods for epitope design and selection have been suggested. We review these in silico approaches for epitope discovery and selection along with their strengths and weaknesses. Finally, we discuss some of the obvious problems in the design of EVs. Conclusion: State-of-the-art in silico approaches to MHC binding prediction yield high accuracies. However, a more thorough understanding of the underlying biological processes and significant amounts of experimental data will be required for the validation and improvement of in silico approaches to the remaining aspects of EV design.

[1]  Christina Kuttler An Algorithm for the Prediction of Proteasomal Cleavages , 2000, German Conference on Bioinformatics.

[2]  Yoram Louzoun,et al.  Precise score for the prediction of peptides cleaved by the proteasome , 2008, Bioinform..

[3]  Shinn-Ying Ho,et al.  POPI: predicting immunogenicity of MHC class I binding peptides by mining informative physicochemical properties , 2007, Bioinform..

[4]  S. H. van der Burg,et al.  Phase I Immunotherapeutic Trial with Long Peptides Spanning the E6 and E7 Sequences of High-Risk Human Papillomavirus 16 in End-Stage Cervical Cancer Patients Shows Low Toxicity and Robust Immunogenicity , 2008, Clinical Cancer Research.

[5]  Ellis L. Reinherz,et al.  Enhancement to the RANKPEP resource for the prediction of peptide binding to MHC molecules using profiles , 2004, Immunogenetics.

[6]  Pingping Guan,et al.  EpiJen: a server for multistep T cell epitope prediction , 2006, BMC Bioinformatics.

[7]  Morten Nielsen,et al.  Large-scale validation of methods for cytotoxic T-lymphocyte epitope prediction , 2007, BMC Bioinformatics.

[8]  Maria V. Tejada-Simon,et al.  Naturally Processed HLA Class II Peptides Reveal Highly Conserved Immunogenic Flanking Region Sequence Preferences That Reflect Antigen Processing Rather Than Peptide-MHC Interactions1 , 2001, The Journal of Immunology.

[9]  Vladimir Brusic,et al.  Evaluation of MHC-II peptide binding prediction servers: applications for vaccine research , 2008, BMC Bioinformatics.

[10]  Søren Buus,et al.  Peptide binding specificity of major histocompatibility complex class I resolved into an array of apparently independent subspecificities: quantitation by peptide libraries and improved prediction of binding , 1996, European journal of immunology.

[11]  Gajendra P. S. Raghava,et al.  Pcleavage: an SVM based method for prediction of constitutive proteasome and immunoproteasome cleavage sites in antigenic sequences , 2005, Nucleic Acids Res..

[12]  David Heckerman,et al.  Leveraging Information Across HLA Alleles/Supertypes Improves Epitope Prediction , 2007, J. Comput. Biol..

[13]  Peter Walden,et al.  Exact prediction of a natural T cell epitope , 1991, European journal of immunology.

[14]  Manoj Bhasin,et al.  Analysis and prediction of affinity of TAP binding peptides using cascade SVM , 2004, Protein science : a publication of the Protein Society.

[15]  Oliver Kohlbacher,et al.  OptiTope—a web server for the selection of an optimal set of peptides for epitope-based vaccines , 2009, Nucleic Acids Res..

[16]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[17]  Tomer Hertz,et al.  PepDist: A New Framework for Protein-Peptide Binding Prediction based on Learning Peptide Distance Functions , 2006, BMC Bioinformatics.

[18]  H. Rammensee,et al.  SYFPEITHI: database for MHC ligands and peptide motifs , 1999, Immunogenetics.

[19]  M F del Guercio,et al.  Several common HLA-DR types share largely overlapping peptide binding repertoires. , 1998, Journal of immunology.

[20]  Marie-Paule Lefranc,et al.  IMGT/3Dstructure-DB and IMGT/StructuralQuery, a database and a tool for immunoglobulin, T cell receptor and MHC structural data , 2004, Nucleic Acids Res..

[21]  Vladimir Brusic,et al.  Prediction of MHC class II-binding peptides using an evolutionary algorithm and artificial neural network , 1998, Bioinform..

[22]  O. Lund,et al.  Definition of supertypes for HLA molecules using clustering of specificity matrices , 2004, Immunogenetics.

[23]  O. Lund,et al.  novel sequence representations Reliable prediction of T-cell epitopes using neural networks with , 2003 .

[24]  O. Lund,et al.  An integrative approach to CTL epitope prediction: A combined algorithm integrating MHC class I binding, TAP transport efficiency, and proteasomal cleavage predictions , 2005, European journal of immunology.

[25]  Arne Elofsson,et al.  Prediction of MHC class I binding peptides, using SVMHC , 2002, BMC Bioinformatics.

[26]  G. Jung,et al.  From combinatorial libraries to MHC ligand motifs, T-cell superagonists and antagonists. , 2001, Biologicals : journal of the International Association of Biological Standardization.

[27]  John Sidney,et al.  Improving MHC binding peptide prediction by incorporating binding data of auxiliary MHC molecules , 2006, Bioinform..

[28]  Cécile Gouttefangeas,et al.  Identification of tumor‐associated MHC class I ligands by a novel T cell‐independent approach , 2000, European journal of immunology.

[29]  Ji Wan,et al.  SVRMHC prediction server for MHC-binding peptides , 2006, BMC Bioinformatics.

[30]  D. Zaller,et al.  Prediction of peptide affinity to HLA DRB1*0401. , 1994, International archives of allergy and immunology.

[31]  Channa K. Hattotuwagama,et al.  MHCPred 2.0 , 2006 .

[32]  P. Opolon,et al.  High vaccination efficiency of low-affinity epitopes in antitumor immunotherapy. , 2004, The Journal of clinical investigation.

[33]  Gunnar Rätsch,et al.  Support Vector Machines and Kernels for Computational Biology , 2008, PLoS Comput. Biol..

[34]  Irini A. Doytchinova,et al.  Towards the in silico identification of class II restricted T-cell epitopes: a partial least squares iterative self-consistent algorithm for affinity prediction , 2003, Bioinform..

[35]  O. Lund,et al.  The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage , 2005, Immunogenetics.

[36]  Naoki Abe,et al.  Empirical Evaluation of a Dynamic Experiment Design Method for Prediction of MHC Class I-Binding Peptides1 , 2002, The Journal of Immunology.

[37]  Claude Beazley,et al.  A Novel Predictive Technique for the MHC Class II Peptide-Binding Interaction , 2003, Molecular medicine.

[38]  Gajendra P. S. Raghava,et al.  ProPred1: Prediction of Promiscuous MHC Class-I Binding Sites , 2003, Bioinform..

[39]  Bjoern Peters,et al.  Identifying MHC Class I Epitopes by Predicting the TAP Transport Efficiency of Epitope Precursors , 2003, The Journal of Immunology.

[40]  Oliver Kohlbacher,et al.  EpiToolKit—a web server for computational immunomics , 2008, Nucleic Acids Res..

[41]  Z. Nagy,et al.  Precise prediction of major histocompatibility complex class II-peptide interaction based on peptide side chain scanning , 1994, The Journal of experimental medicine.

[42]  J. Sidney,et al.  Improved Immunogenicity of an Immunodominant Epitope of the Her-2/neu Protooncogene by Alterations of MHC Contact Residues1 , 2004, The Journal of Immunology.

[43]  Gajendra P. S. Raghava,et al.  ProPred: prediction of HLA-DR binding sites , 2001, Bioinform..

[44]  Tomer Hertz,et al.  Predicting Protein-Peptide Binding Affinity by Learning Peptide-Peptide Distance Functions , 2005, RECOMB.

[45]  R. Orlando,et al.  A new liquid chromatography/tandem mass spectrometric approach for the identification of class I major histocompatibility complex associated peptides that eliminates the need for bioassays. , 1999, Rapid communications in mass spectrometry : RCM.

[46]  Y. Z. Chen,et al.  Prediction of MHC-binding peptides of flexible lengths from sequence-derived structural and physicochemical properties. , 2007, Molecular immunology.

[47]  P. Dönnes,et al.  Integrated modeling of the major events in the MHC class I antigen processing pathway , 2005, Protein science : a publication of the Protein Society.

[48]  Pierre Baldi,et al.  Bioinformatics - the machine learning approach (2. ed.) , 2000 .

[49]  Oliver Kohlbacher,et al.  SNEP: SNP-derived Epitope Prediction program for minor H antigens , 2005, Immunogenetics.

[50]  A Sette,et al.  The peptide-binding motif for the human transporter associated with antigen processing , 1995, The Journal of experimental medicine.

[51]  Gajendra P. S. Raghava,et al.  SVM based method for predicting HLA-DRB1*0401 binding peptides in an antigen sequence , 2004, Bioinform..

[52]  Yao-Tseng Chen,et al.  CD8+ T cell responses against a dominant cryptic HLA-A2 epitope after NY-ESO-1 peptide immunization of cancer patients , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[53]  P. Kloetzel,et al.  Modeling the MHC class I pathway by combining predictions of proteasomal cleavage,TAP transport and MHC class I binding , 2005, Cellular and Molecular Life Sciences CMLS.

[54]  H Mamitsuka,et al.  Predicting peptides that bind to MHC molecules using supervised learning of hidden markov models , 1998, Proteins.

[55]  Hans-Georg Rammensee,et al.  The Tübingen approach: identification, selection, and validation of tumor-associated HLA peptides for cancer therapy , 2004, Cancer Immunology, Immunotherapy.

[56]  Jonathan J. Lewis,et al.  Heteroclitic Immunization Induces Tumor Immunity , 1998, The Journal of experimental medicine.

[57]  P. Kloetzel,et al.  MAPPP: MHC class I antigenic peptide processing prediction. , 2003, Applied bioinformatics.

[58]  V. Brusic,et al.  Evaluation of MHC class I peptide binding prediction servers: Applications for vaccine research , 2008, BMC Immunology.

[59]  A. Vitiello,et al.  The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. , 1994, Journal of immunology.

[60]  P. Kloetzel,et al.  The cleavage preference of the proteasome governs the yield of antigenic peptides , 1995, The Journal of experimental medicine.

[61]  O. Lund,et al.  The Immune Epitope Database and Analysis Resource: From Vision to Blueprint , 2005, PLoS biology.

[62]  V Brusic,et al.  Relationship between peptide selectivities of human transporters associated with antigen processing and HLA class I molecules. , 1998, Journal of immunology.

[63]  J. Wolchok,et al.  Immunological validation of the EpitOptimizer program for streamlined design of heteroclitic epitopes. , 2007, Vaccine.

[64]  Vladimir Brusic,et al.  Prediction of promiscuous peptides that bind HLA class I molecules , 2002, Immunology and cell biology.

[65]  David Heckerman,et al.  Coping with Viral Diversity in HIV Vaccine Design , 2007, PLoS Comput. Biol..

[66]  J. Sidney,et al.  Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism , 1999, Immunogenetics.

[67]  D. Flower,et al.  Additive method for the prediction of protein-peptide binding affinity. Application to the MHC class I molecule HLA-A*0201. , 2002, Journal of proteome research.

[68]  M. V. Regenmortel,et al.  Mapping Epitope Structure and Activity: From One-Dimensional Prediction to Four-Dimensional Description of Antigenic Specificity , 1996 .

[69]  Channa K. Hattotuwagama,et al.  AntiJen: a quantitative immunology database integrating functional, thermodynamic, kinetic, biophysical, and cellular data , 2005, Immunome research.

[70]  D. DeLuca,et al.  A modular concept of HLA for comprehensive peptide binding prediction , 2006, Immunogenetics.

[71]  N. Senzer,et al.  Phase I Trial of sequential administration of recombinant DNA and adenovirus expressing L523S protein in early stage non-small-cell lung cancer. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[72]  Chee Keong Kwoh,et al.  PREDTAP: a system for prediction of peptide binding to the human transporter associated with antigen processing , 2006, Immunome research.

[73]  T. N. Bhat,et al.  The Protein Data Bank , 2000, Nucleic Acids Res..

[74]  T. Hanai,et al.  Hidden Markov model-based prediction of antigenic peptides that interact with MHC class II molecules. , 2002, Journal of bioscience and bioengineering.

[75]  Gajendra P. S. Raghava,et al.  MHCBN: a comprehensive database of MHC binding and non-binding peptides , 2003, Bioinform..

[76]  Pingping Guan,et al.  MHCPred: a server for quantitative prediction of peptide-MHC binding , 2003, Nucleic Acids Res..

[77]  John Sidney,et al.  Structural Features of Peptide Analogs of Human Histocompatibility Leukocyte Antigen Class I Epitopes That Are More Potent and Immunogenic than Wild-Type Peptide , 2001, The Journal of experimental medicine.

[78]  Morten Nielsen,et al.  Modeling the adaptive immune system: predictions and simulations , 2007, Bioinform..

[79]  Ferry Ossendorp,et al.  Efficient Identification of Novel Hla-A*0201–Presented Cytotoxic T Lymphocyte Epitopes in the Widely Expressed Tumor Antigen Prame by Proteasome-Mediated Digestion Analysis , 2001, The Journal of experimental medicine.

[80]  Yang Dai,et al.  Prediction of MHC class II binding peptides based on an iterative learning model , 2005, Immunome research.

[81]  Bjoern Peters,et al.  Automated generation and evaluation of specific MHC binding predictive tools: ARB matrix applications , 2005, Immunogenetics.

[82]  Guido Ferrari,et al.  Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteers. , 2007, Vaccine.

[83]  D. Rognan,et al.  Predicting binding affinities of protein ligands from three-dimensional models: application to peptide binding to class I major histocompatibility proteins. , 1999, Journal of medicinal chemistry.

[84]  Ora Schueler-Furman,et al.  Learning MHC I - peptide binding , 2006, ISMB.

[85]  Anne S De Groot,et al.  HIV vaccine development by computer assisted design: the GAIA vaccine. , 2005, Vaccine.

[86]  J A Koziol,et al.  Prediction of binding to MHC class I molecules. , 1995, Journal of immunological methods.

[87]  O. Schueler‐Furman,et al.  Structure‐based prediction of binding peptides to MHC class I molecules: Application to a broad range of MHC alleles , 2000, Protein science : a publication of the Protein Society.

[88]  C. Slingluff,et al.  Immunologic and Clinical Outcomes of a Randomized Phase II Trial of Two Multipeptide Vaccines for Melanoma in the Adjuvant Setting , 2007, Clinical Cancer Research.

[89]  Jean-Philippe Vert,et al.  Efficient peptide-MHC-I binding prediction for alleles with few known binders , 2008, Bioinform..

[90]  John Sidney,et al.  A Systematic Assessment of MHC Class II Peptide Binding Predictions and Evaluation of a Consensus Approach , 2008, PLoS Comput. Biol..

[91]  Gajendra P.S. Raghava,et al.  Prediction of CTL epitopes using QM, SVM and ANN techniques. , 2004, Vaccine.

[92]  John Sidney,et al.  Examining the independent binding assumption for binding of peptide epitopes to MHC-I molecules , 2003, Bioinform..

[93]  B. Korber,et al.  Expanded Breadth of the T-Cell Response to Mosaic Human Immunodeficiency Virus Type 1 Envelope DNA Vaccination , 2008, Journal of Virology.

[94]  S. Brunak,et al.  Prediction of proteasome cleavage motifs by neural networks. , 2002, Protein engineering.

[95]  C. Slingluff,et al.  A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer , 2008, Journal of immunotherapy.

[96]  Gajendra P.S. Raghava,et al.  A hybrid approach for predicting promiscuous MHC class I restricted T cell epitopes , 2007, Journal of Biosciences.

[97]  P. Kloetzel,et al.  A kinetic model of vertebrate 20S proteasome accounting for the generation of major proteolytic fragments from oligomeric peptide substrates. , 2000, Biophysical journal.

[98]  N. Marchand-Geneste,et al.  Synthetic anticancer vaccine candidates: rational design of antigenic peptide mimetics that activate tumor-specific T-cells. , 2007, Journal of medicinal chemistry.

[99]  A. D. De Groot,et al.  Prediction of well-conserved HIV-1 ligands using a matrix-based algorithm, EpiMatrix. , 1998, Vaccine.

[100]  Vladimir Brusic,et al.  A neural network model approach to the study of human TAP transporter , 1998, Silico Biol..

[101]  Morten Nielsen,et al.  Pan-specific MHC class I predictors: a benchmark of HLA class I pan-specific prediction methods , 2009, Bioinform..

[102]  Nebojsa Jojic,et al.  Shift-Invariant Adaptive Double Threading: Learning MHC II - Peptide Binding , 2007, RECOMB.

[103]  P. Kloetzel,et al.  A theoretical approach towards the identification of cleavage-determining amino acid motifs of the 20 S proteasome. , 1999, Journal of molecular biology.

[104]  Anthony Kusalik,et al.  Strength in numbers: achieving greater accuracy in MHC-I binding prediction by combining the results from multiple prediction tools , 2007, Immunome research.

[105]  Ryuji Kato,et al.  Hidden Markov model-based approach as the first screening of binding peptides that interact with MHC class II molecules , 2003 .

[106]  Avner Schlessinger,et al.  Towards a consensus on datasets and evaluation metrics for developing B‐cell epitope prediction tools , 2007, Journal of molecular recognition : JMR.

[107]  Morten Nielsen,et al.  The PickPocket method for predicting binding specificities for receptors based on receptor pocket similarities: application to MHC-peptide binding , 2009, Bioinform..

[108]  R. R. Mallios,et al.  Predicting class II MHC/peptide multi-level binding with an iterative stepwise discriminant analysis meta-algorithm , 2001, Bioinform..

[109]  U. Şahin,et al.  Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices , 1999, Nature Biotechnology.

[110]  Darren R Flower,et al.  Coupling In Silico and In Vitro Analysis of Peptide-MHC Binding: A Bioinformatic Approach Enabling Prediction of Superbinding Peptides and Anchorless Epitopes , 2004, The Journal of Immunology.

[111]  Oliver Kohlbacher,et al.  A Mathematical Framework for the Selection of an Optimal Set of Peptides for Epitope-Based Vaccines , 2008, PLoS Comput. Biol..

[112]  Z. Cao,et al.  MHC-BPS: MHC-binder prediction server for identifying peptides of flexible lengths from sequence-derived physicochemical properties , 2006, Immunogenetics.

[113]  J. Berzofsky,et al.  Two novel T cell epitope prediction algorithms based on MHC-binding motifs; comparison of predicted and published epitopes from Mycobacterium tuberculosis and HIV protein sequences. , 1995, Vaccine.

[114]  A. Sette,et al.  Epitope-based vaccines: an update on epitope identification, vaccine design and delivery. , 2003, Current opinion in immunology.

[115]  Manoj Bhasin,et al.  Prediction of promiscuous and high-affinity mutated MHC binders. , 2003, Hybridoma and hybridomics.

[116]  James McCluskey,et al.  More than one reason to rethink the use of peptides in vaccine design , 2007, Nature Reviews Drug Discovery.

[117]  James Robinson,et al.  IPD—the Immuno Polymorphism Database , 2004, Nucleic acids research.

[118]  Morten Nielsen,et al.  A Community Resource Benchmarking Predictions of Peptide Binding to MHC-I Molecules , 2006, PLoS Comput. Biol..

[119]  E. Reinherz,et al.  Prediction of MHC class I binding peptides using profile motifs. , 2002, Human immunology.

[120]  Richard Simon,et al.  Genomewide Conserved Epitope Profiles of HIV-1 Predicted by Biophysical Properties of MHC Binding Peptides , 2004, J. Comput. Biol..

[121]  Christian Bréchot,et al.  Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. , 2006, Vaccine.

[122]  James Theiler,et al.  Polyvalent vaccines for optimal coverage of potential T-cell epitopes in global HIV-1 variants , 2007, Nature Medicine.

[123]  Søren Brunak,et al.  Improved prediction of MHC class I and class II epitopes using a novel Gibbs sampling approach , 2004, Bioinform..

[124]  Yoram Louzoun,et al.  Virus-epitope vaccine design: informatic matching the HLA-I polymorphism to the virus genome. , 2007, Molecular immunology.

[125]  Morten Nielsen,et al.  Quantitative Predictions of Peptide Binding to Any HLA-DR Molecule of Known Sequence: NetMHCIIpan , 2008, PLoS Comput. Biol..

[126]  O. Lund,et al.  NetMHCpan, a Method for Quantitative Predictions of Peptide Binding to Any HLA-A and -B Locus Protein of Known Sequence , 2007, PloS one.

[127]  Hermann-Georg Holzhütter,et al.  Modeling the in vitro 20S proteasome activity: the effect of PA28-alphabeta and of the sequence and length of polypeptides on the degradation kinetics. , 2008, Journal of molecular biology.

[128]  O. Lund,et al.  NetMHCpan, a method for MHC class I binding prediction beyond humans , 2008, Immunogenetics.

[129]  Trevor Hastie,et al.  The Elements of Statistical Learning , 2001 .

[130]  S Brunak,et al.  Sensitive quantitative predictions of peptide-MHC binding by a 'Query by Committee' artificial neural network approach. , 2003, Tissue antigens.

[131]  S. Holmes,et al.  Diversity and Recognition Efficiency of T Cell Responses to Cancer , 2004, PLoS medicine.

[132]  H. Rammensee,et al.  Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules , 1991, Nature.